On November 11, Caris Life Sciences, Inc. rose 4.79% in Pre-Market Trading, trading at $25.6 per share, with turnover of $96,200.
The move came after the company’s stronger-than-expected third-quarter results and higher full-year revenue guidance, with the stock rebounding after heavy post-earnings pressure while analyst views remained mixed.
Caris Life Sciences, Inc. reported third-quarter EPS of $0.05, above consensus expectations of $0.03 to $0.04, while revenue rose to $275.4 million from $216.8 million a year earlier and exceeded the roughly $255.4 million forecast. The company also raised full-year revenue guidance to $1.04 billion to $1.05 billion from $1.03 billion to $1.04 billion previously. Even so, EPS was below the prior-year level of $0.08, and recent analyst actions remained divided, with Citigroup maintaining Buy and Piper Sandler maintaining Neutral, underscoring continued debate over valuation and growth durability.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments